Waverly Advisors LLC Acquires 11,963 Shares of Edwards Lifesciences Co. (NYSE:EW)

Waverly Advisors LLC boosted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 223.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,314 shares of the medical research company's stock after purchasing an additional 11,963 shares during the period. Waverly Advisors LLC's holdings in Edwards Lifesciences were worth $1,282,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $30,000. Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $54,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $62,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president now owns 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares of the company's stock, valued at $4,106,859.33. The trade was a 9.45% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,692 shares of company stock worth $4,822,074. Insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of several analyst reports. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Citigroup restated a "buy" rating and issued a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Evercore ISI cut their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $80.20.

Edwards Lifesciences Stock Performance

EW stock traded up $0.06 on Thursday, hitting $76.72. The company had a trading volume of 606,801 shares, compared to its average volume of 5,141,624. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock's 50-day simple moving average is $73.09 and its 200 day simple moving average is $72.25. The stock has a market cap of $45.00 billion, a price-to-earnings ratio of 11.00, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the firm earned $0.66 earnings per share. The company's quarterly revenue was up 6.2% on a year-over-year basis. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.